Chikungunya vaccine candidate causes successful development of antibodies against the virus

Chikungunya Vaccine Candidate Passes Phase I Clinical Trials

Chikungunya vaccine candidate causes successful development of antibodies against the virus Chikungunya, a mosquito borne virus, has recently been responsible for outbreaks in the Caribbean and the Pacific. Although the disease is not usually fatal, it causes similar symptoms to a bad flu: muscle aches, malaise and headaches. However, one of the unique aspects of the virus is that it …

Map of vaccine-preventable outbreaks

This interactive map from the Council on Foreign Relations charts global outbreaks of vaccine preventable diseases since 2008. Whilst some of the data may not be all that surprising, the prevalence of whooping cough in the US, and mumps and measles in Europe is cause for concern. Perhaps particularly noteworth is the number of cases of measles and mumps in …

Enhancing existing vaccines, developing technologies for biodefense vaccines

Biodefense is traditionally a term associated with defensive measures taken against biological attack. Dr Michael Kurilla, Director, Office of BioDefense Research Affairs & Associate Director for BioDefense Product Development, DMID, NIAID, NIH, DHHS, spoke at the World Vaccine Congress 2012 in Washington on the application of biodefense to existing vaccines to prevent the potential impact from future pandemics. The necessity …

Reverse vaccinology – the key to novel antigens

The basic idea behind Reverse Vaccinology is that an entire pathogenic genome can be screened using bioinformatics approaches to find genes. Next, those genes are filtered for desirable attributes that would make good vaccine targets such as outer membrane proteins. Those proteins then undergo normal wet lab testing for immune responses. The term was coined by Dr Rino Rappuoli, now …

Download: Discover the 6 key growth areas in the #vaccine industry

As the vaccine industry grows year on year, isn’t it essential you benchmark your strategies against the competition? With this in mind we organized this year’s World Vaccine Congress Lyon, focusing on precisely those top 6 key growth areas that will help you stay at the forefront of the industry. Expert speakers and industry strategists will come together in Lyon …

Dr Michael Kurilla at #wvcusa – Enhancing existing vaccines, developing technologies for biodefence vaccines

Last week at the World Vaccine Congress Dr Michael Kurilla, Director, Office of BioDefense Research Affairs & Associate Director for BioDefense Product Development at DMID, NIAID, NIH, DHHS delivered a presentation on Enhancing existing vaccines, developing technologies for biodefence vaccines. Dr Kurilla talked about the aspect of vaccination and how to enhance vaccination technologies. The current development path for this …